Efficacy of epoetin-beta 30.000 IU/week in correcting anaemia in patients with gastrointestinal tumours subjected to concomitant chemoradiotherapy
Clin. transl. oncol. (Print)
; 12(12): 843-848, dic. 2010.
Article
in En
| IBECS
| ID: ibc-124384
Responsible library:
ES1.1
Localization: BNCS
ABSTRACT
OBJECTIVE:
The aim of the project was to assess the effectiveness and safety of weekly epoetin-beta (EB) in patients with gastrointestinal cancer (GIC) subjected to concomitant chemoradiotherapy (CCTRT).METHODS:
In this clinical prospective and multicentre cohort study EB was administered at a dose of 30,000 IU/ week, during CCTRT and in the four weeks thereafter, and suspended if haemoglobin (Hb) increased >2 g/dl or Hb >12-13 g/dl. Effectiveness was defi ned as Hb increase ≥1 g/dl vs. baseline. Time to response, treatment toxicity and transfusion requirements were also assessed.RESULTS:
EB was effective in 75.8% of the evaluable population within a median of four weeks from EB initiation, without blood transfusions. Over 80% of all patients remained below the threshold (Hb ≤13 g/dl) and no study drug-related adverse reactions were recorded.CONCLUSION:
Weekly EB proved to be effective and well tolerated by patients with GIC subjected to CCTRT (AU)
Search on Google
Collection:
06-national
/
ES
Database:
IBECS
Main subject:
Erythropoietin
/
Gastrointestinal Neoplasms
/
Anemia
/
Antineoplastic Agents
Type of study:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
Language:
En
Journal:
Clin. transl. oncol. (Print)
Year:
2010
Document type:
Article